Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (note: input metadata listed "TALPHERA, INC." but the filing text identifies the registrant as AcelRx Pharmaceuticals, Inc.) on April 7, 2018. The report details a corporate governance event regarding the granting of performance-based stock option awards to employees and named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the equity compensation grant:
- Total Shares Awarded: Approximately 917,543 shares.
- Exercise Price: $2.23 per share (based on the closing sales price on April 9, 2018).
Material Changes
The material change reported is the implementation of a new type of performance-based stock option award under the Company's 2011 Equity Incentive Plan. This differs from standard time-based grants as vesting is contingent upon regulatory milestones.
Guidance, Outlook, and Management Commentary
Performance Milestones:
- 50% Vesting: Triggered upon FDA commercial approval of the New Drug Application (NDA) for DSUVIA on or before February 15, 2019.
- Remaining 50% Vesting: Triggered on the one-year anniversary of the FDA approval date.
- Expiration Condition: If FDA approval is not obtained by February 15, 2019, all performance-based options will expire unexercised.
Named Executive Officer Allocations:
| Officer | Title | Shares Awarded |
|---|---|---|
| Vincent Angotti | Chief Executive Officer | 192,500 |
| Raffi Asadorian | Chief Financial Officer | 81,125 |
| Anil Dasu | Chief Engineering Officer | 63,250 |
| Larry Hamel | Chief Development Officer | 52,250 |
| Pamela Palmer | Chief Medical Officer | 95,150 |
Investor Verification Checklist
- Verify the current status of the DSUVIA New Drug Application (NDA) and whether FDA approval was achieved by the February 15, 2019 deadline.
- Confirm the total number of shares outstanding and the dilution impact of the 917,543 awarded options.
- Review the full text of the Performance-Based Stock Option Award agreement filed in the subsequent Form 10-Q for the quarter ended March 31, 2018.
- Check for any subsequent filings regarding the expiration of these options if the FDA approval deadline was missed.